|

AUCD Community Inclusion

AUCD’s Community Inclusion Team supports the University Centers for Excellence in Developmental Disabilities (UCEDD) Network in partnership with the Administration for Community Living.

Learn More
|

AUCD Maternal and Child Health Engagement

AUCD’s Maternal and Child Health Engagement supports the Autism CARES Programs, including LEND and DBP Programs.

Learn More
|

AUCD Public Health

AUCD’s Public Health Team works to create health promotion and public health efforts that include people with disabilities.

Learn More
|

AUCD Emerging Leaders Community

AUCD Emerging Leaders are a part of a community that includes trainees, early career professionals, self-advocates, and family members from AUCD member Centers and Programs.

Learn More

Donate

Project

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) in Fragile X Syndrome

Center:

KS-Schiefelbusch Institute for Life Span Studies, UCEDD/LEND

Fiscal Year:

2013

Contact Information:

Kathryn Ellerbeck
[email protected]
913-588-5781

Project Description:

STX209 is an experimental, or investigational, form of the medication called baclofen that is approved by the FDA to treat stiff muscles due to cerebral palsy or other types of brain or spinal cord injury. There is some evidence that baclofen may help with irritability in people with developmental disabilities. STX209 is an investigational drug in a tablet that dissolves in the mouth and is not yet approved by the FDA for treatment of FXS. STX209 is not being tested as a treatment for FXS but only as a possible treatment for social withdrawal symptoms in patients with FXS.

Keyword(s):

Core Function(s):

Performing Research or Evaluation

Area of Emphasis

Health-Related Activities

Target Audience:

Children/Adolescents with Disabilities/SHCN

Unserved or Under-served Populations:

Specific Groups

Primary Target Audience Geographic Descriptor:

State, Regional

Funding Source: